Validation of Oxygen Nanosensor in Mitochondrial Myopathy
NCT04086329
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
Past mitochondrial disease treatment studies have been unsuccessful in determining treatment efficacy, and a major factor has been the lack of validated biomarkers in mitochondrial myopathy (MM). There is currently a growing number of potential new treatments to be tested through MM clinical intervention trials, which has created a pressing need for quantitative biomarkers that reliably reflect MM disease severity, progression, and therapeutic response.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Mitochondrial Myopathies
- Mitochondrial Diseases
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Children's Hospital of Philadelphia
- Last updated on ClinicalTrials.gov
- February 18, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Pennsylvania · 1
- The Children's Hospital of Philadelphia · Philadelphia, PA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.